文献速递糖尿病

无管路自动胰岛素输注系统对比每日多次注射治疗HbA1c升高的1型糖尿病儿童和成人:RADIANT多中心随机对照试验

Tubeless automated insulin delivery versus multiple daily injections in children and adults with type 1 diabetes with elevated HbA1c (RADIANT): a multicentre, international, parallel-group, open-label, randomised, controlled trial.
PubMed 文献 · Lancet Diabetes Endocrinol · 2026-02-23

BACKGROUND: Automated insulin delivery (AID) systems have been shown to improve glycaemic outcomes in people with type 1 diabetes managed with insulin pump therapy.…

要点

  • 13周内两组均无严重低血糖或糖尿病酮症酸中毒事件
  • AID组报告39例不良事件(28例参与者),对照组报告3例不良事件(3例参与者)

核心结论

  • 在1型糖尿病成人和儿童中,从每日多次注射直接转换为无管路AID可改善血糖控制且无安全性担忧,支持AID作为标准治疗选择。

研究设计与样本

  • 多中心、国际、平行组、开放标签、随机对照试验,在英国、比利时和法国的19家医院进行。
  • 主要结局为13周时HbA1c的校正组间差异,在改良意向治疗人群(所有随机分配参与者)中评估。

主要发现

  • 13周试验期间,两组均未发生严重低血糖或糖尿病酮症酸中毒事件。
  • AID组28例参与者报告39例不良事件,对照组3例参与者报告3例不良事件;AID组发生2例严重不良事件(川崎病和急性冠脉综合征),与研究装置或操作无关。

临床怎么用

  • 对于使用每日多次注射且HbA1c升高的1型糖尿病成人和儿童,可考虑直接转换为无管路AID以改善血糖控制。
  • 转换过程中未观察到严重低血糖或糖尿病酮症酸中毒的安全性信号。

局限性

  • 开放标签设计,参与者和研究团队未对分组设盲。
  • 随访时间较短(13周)。
  • 对照组为非AID的每日多次注射,未与其他AID系统直接比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Automated insulin delivery (AID) systems have been shown to improve glycaemic outcomes in people with type 1 diabetes managed with insulin pump therapy. No randomised studies have evaluated the benefits of tubeless AID in both adults and children with suboptimal glycaemia compared with multiple daily injections. We aimed to evaluate the safety and efficacy of a tubeless AID system compared with multiple daily injections in this population. METHODS: RADIANT was a multicentre, international, parallel-group, open-label, randomised, controlled trial done in 19 hospitals in the UK, Belgium, and France. Participants aged 4-70 years with type 1 diabetes managed with multiple daily injections and continuous glucose monitoring and who had HbA1c levels of 7·5-11% (58-97 mmol/mol) were randomly assigned (2:1) to tubeless AID or control (multiple daily injections) using a permuted-block design. Participant and study teams were not masked to group allocation. The primary outcome was the adjusted between-group difference in HbA1c at 13 weeks assessed for superiority. Primary and safety outcomes were assessed in the modified intention-to-treat population (all randomly assigned participants). The study is registered with ClinicalTrials.gov, NCT05923827, and has been completed. FINDINGS: Between Sept 11, 2023, and April 26, 2024, 188 participants were randomly assigned to the AID group (n=125) or the control group (n=63). The AID group had a greater reduction in HbA1c, from 8·1% (SD 0·7; 65 mmol/mol [SD 7·7]) at baseline to 7·2% (0·6; 55 mmol/mol [6·6]) at 13 weeks, compared with the control group, from 8·1% (0·6; 65mmol/mol [6·6]) at baseline to 8·0% (0·7; 64 mmol/mol [7·7]) at 13 weeks, with an adjusted mean difference of -0·8% (95% CI -1·0 to -0·6; -8·7 mmol/mol [95% CI -10·9 to -6·6]; p<0·0001). During the 13-week trial, no episodes of severe hypoglycaemia or diabetic ketoacidosis occurred in either treatment group. 39 adverse events were reported among 28 participants in the AID group, and three adverse events among three participants in the control group. Two serious adverse events (Kawasaki disease and acute coronary syndrome) occurred in the AID group unrelated to the study device or procedure. INTERPRETATION: Results from this trial show the clinical efficacy of direct transition from multiple daily injections to tubeless AID in adults and children with type 1 diabetes, with no safety concerns, supporting AID as a therapeutic option within standard of care for people with type 1 diabetes. FUNDING: Insulet Corporation.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Wilmot EG, Beltrand J, Guerci B, et al. Tubeless automated insulin delivery versus multiple daily injections in children and adults with type 1 diabetes with elevated HbA1c (RADIANT): a multicentre, international, parallel-group, open-label, randomised, controlled trial. Lancet Diabetes Endocrinol. 2026. PMID: 41747751. doi:10.1016/S2213-8587(25)00364-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。